Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension



Status:Completed
Conditions:Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:11/3/2017
Start Date:October 2013
End Date:October 2016

Use our guide to learn which trials are right for you!

A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment

The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone -
on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic
medications (AEDs).

This is a 2-cohort study comprised of 2 phases in each cohort. Phase 1 is a double-blind
phase followed by Phase 2, an open-label phase. Cohort 1 will provide tolerability, safety,
and PK information for ganaxolone 1200mg/d, 1800mg/d and placebo. Cohort 2 will investigate
the efficacy, tolerability and safety of ganaxolone 1800mg/d compared to placebo. Cohort 1
(N= approximately 50) will enroll into a 67-week study comprised of a 4-week prospective
baseline period plus 4 week retrospective baseline followed by two treatment phases: a 9-week
randomized DB placebo-controlled treatment phase followed by a 52-week open label (OL)
treatment phase. Cohort 2 (N=150) will enroll into a 72-week study comprised of a 8-week
prospective baseline period followed by two treatment phases: a 14-week randomized DB
placebo-controlled treatment phase followed by a 52-week open label (OL) treatment phase.

Inclusion Criteria:

- Able to give informed consent in writing, or have a legally authorized representative
able to do so

- Willing to enter and participate for the full term of the double blind phase and
willing to enter into the open-label phase

- Male or female outpatients > 18 years of age

- Have a confident diagnosis of drug-resistant epilepsy with partial-onset seizures
(POS), with or without secondary generalization, for ≥2 years. Have residual POS
despite having been treated in the past with at least 2 approved anti-epilepsy drugs
(AEDs) either alone or in combination

- Based on history, subjects would be anticipated to have at least 3 POS during each
4-week Baseline period and unlikely to have 21 or more consecutive POS-free days

- Currently being treated and maintained with a stable regimen of 1, 2, or 3 AEDs

- Able and willing to maintain daily seizure calendar

- Able and willing to take drug with food twice daily

- Sexually active women of childbearing potential must use acceptable birth control and
have a negative pregnancy test at all visits

Exclusion Criteria:

- Have had previous exposure to ganaxolone

- Known sensitivity or allergy to any component in the study drug, progesterone, or
other related steroid compounds

- Exposure to any investigational drug or device < 30 days prior to screening, or plans
to take another investigational drug at any time during the study

- Time of onset of epilepsy treatment < 2 years prior to enrollment

- Have generalized epilepsy, such as Lennox-Gastaut syndrome, juvenile myoclonic
epilepsy, absence epilepsy, or non-epileptic seizures within the last 12- month period
prior to study entry

- Have less than 3 POS seizures in a 28-day period or more than 21 consecutive
seizure-free days during the Baseline period

- Have only simple partial seizures without any observable motor component

- Have innumerable seizures or status epilepticus within the last 12-months prior to
screening

- Have more than 100 POS per 4-week Baseline period

- Have seizures secondary to illicit drug or alcohol use, infection, neoplasm,
demyelinating disease, degenerative neurological disease, or central nervous system
(CNS) disease deemed progressive, metabolic illness, or progressive degenerative
disease

- Current use of vigabatrin is not permitted. If prior use of vigabatrin, must have
documented stable visual fields

- Current use of ezogabine is not permitted. If prior use, must have been off the
medication for at least 3 months prior to screening and have had documented normal
fundoscopic exam by ophthalmologist

- Are planning surgery, or to be evaluated for surgery, during the double blind phase to
control seizures including VNS implantation

- Are suffering from acute or progressive neurological disease, moderate or severe
psychiatric disease, or severe mental abnormalities that are likely to require changes
in drug therapy during the double blind portion of the study or interfere with the
objectives of the study or the ability to adhere to the protocol requirements

- Have a history of an actual suicide attempt in the last 5 years or more than 1
lifetime suicide attempt

- Have a positive urine drug screen at Screening or meet criteria for current or
historical Substance Use Disorder (DSM-V criteria) within the past 5 years.

- Have any medical condition that, in the investigator's judgment, is considered to be
clinically significant and could potentially affect subject safety or study outcome,
including but not limited to: clinically significant cardiac, renal, pulmonary,
gastrointestinal, hematologic or hepatic conditions; or a condition that affects the
absorption, distribution, metabolism or excretion of drugs

- Have elevated ALT (SGPT) or AST (SGOT) greater than 3 times upper limits of normal, or
total bilirubin greater than 1.5 time ULN

- Have a history of malignancy within the past 2 years, with the exception of basal cell
carcinoma

- Are currently following or planning to follow a ketogenic diet

- Use of dietary supplements or herbal preparations are not permitted if subject has
been using them consistently for less than 6 months prior to screening, or does not
plan on remaining on stable doses for the duration of the double blind phase. Use of
St. John's Wort is not permitted

- Females who are pregnant, currently breastfeeding or planning to become pregnant
during the duration of the study

- A history of chronic noncompliance with drug regimens

- Inability to withhold grapefruit and grapefruit juice from diet during the entire
clinical trial
We found this trial at
34
sites
Oklahoma City, Oklahoma 73112
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
736 E Bullard Ave
Fresno, California 93710
559-437-9700
?
mi
from
Fresno, CA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bethesda, Maryland 20817
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
?
mi
from
Canton, OH
Click here to add this to my saved trials
Cedarhurst, New York
?
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
?
mi
from
Chesterfield, MO
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75251
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Golden Valley, Minnesota 55422
?
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Lexington, Kentucky 40504
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Miami, Florida 33176
?
mi
from
Miami, FL
Click here to add this to my saved trials
Middletown, New York 10941
?
mi
from
Middletown, NY
Click here to add this to my saved trials
259 1st St
Mineola, New York 11501
(516) 663-0333
Winthrop University Hospital Founded in 1896 by a group of local physicians and concerned citizens,...
?
mi
from
Mineola, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10017
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73112
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19140
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85004
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Port Charlotte, Florida 33952
?
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Renton, Washington 98057
?
mi
from
Renton, WA
Click here to add this to my saved trials
Santa Monica, California 90404
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Sun City, Arizona 85351
?
mi
from
Sun City, AZ
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials